@incollection{vanRheenenStroomezandvanAmerongenetal.2021,
  author    = {Ronald W. J. van Rheenen and Gilles N. Stroomezand and Jacoba P. van Amerongen and Andreas Otte and Peter Paul De Deyn and Rudi A. J. O. Dierckx},
  title     = {Perfusion SPECT: Its Role in the Diagnosis and Differential Diagnosis of Alzheimer's Disease, with Particular Emphasis on Guidelines},
  series = {PET and SPECT in Neurology},
  editor    = {Rudi A. J. O. Dierckx and Andreas Otte and Erik F. J. de Vries and Aren van Waarde and Klaus L. Leenders},
  edition   = {2.},
  publisher = {Springer International Publishing},
  address   = {Cham, Schweiz},
  isbn      = {978-3-030-53167-6 (Hardcover)},
  doi       = {10.1007/978-3-030-53168-3\_14},
  pages     = {453 -- 468},
  year      = {2021},
  abstract  = {Dementia is a clinical diagnosis reflecting many possible underlying pathologies, for example, vascular dementia and neurodegenerative disorders such as frontotemporal dementia, Lewy body-type disorder or Alzheimer’s disease (AD). The breakthrough of 99mtechnetium-labelled perfusion tracers in the 1990s resulted in many SPECT studies of flow changes in AD. In the first decade of 2000, the role of perfusion SPECT was shifted from diagnosis towards differential diagnosis, parallel to the growing attention for diagnosing early stages of dementia. Previously a diagnosis based largely on a process of exclusion, new guidelines have emerged increasingly employing positive criteria to establish the diagnosis, including neuroimaging biomarkers. Nowadays, FDG PET has largely limited the role of perfusion SPECT, although it is still considered a valuable and cost-effective alternative when PET is not available.},
  language  = {en}
}